ONCAlert | 2017 San Antonio Breast Cancer Symposium

How Ibrutinib Has Transformed the Treatment Paradigm of CLL

Javier Pinilla-Ibarz, MD, PhD
Published Online:11:23 AM, Thu September 21, 2017

Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses how ibrutinib (Imbruvica) has transformed the treatment landscape of chronic lymphocytic leukemia (CLL).
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.